FDA approves UCB's Zilbrysq as first daily autoinjector for generalized myasthenia gravis

The FDA approved UCB's Zilbrysq (zilucoplan) as the first self-administered, once-daily autoinjector option for generalized myasthenia gravis in adult patients who are anti-AChR antibody-positive. Generalized myasthenia gravis is a rare autoimmune disease affecting 150 to 350 people per million worldwide.

Detected & updated continuously · Source: Nebula